# Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

> **NCT06428396** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Belzutifan
- **DRUG:** Fulvestrant
- **DRUG:** Everolimus
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT06428396
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2027-05-05
- **Final completion:** 2028-12-25
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06428396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06428396, "Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06428396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*